Calidi Biotherapeutics, Inc. (CLDI)
Automate Your Wheel Strategy on CLDI
With Tiblio's Option Bot, you can configure your own wheel strategy including CLDI - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol CLDI
- Rev/Share 0.5228
- Book/Share 0.7216
- PB 8.1761
- Debt/Equity 1.9337
- CurrentRatio 1.13
- ROIC -3.2292
- MktCap 14421260.0
- FreeCF/Share -1.3333
- PFCF -3.7595
- PE -0.7265
- Debt/Assets 0.3648
- DivYield 0
- ROE 1804.7273
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 4
- P/B Score 2
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
Calidi Biotherapeutics Announces Exercise of Warrants for $4.6 Million of Gross Proceeds
Published: July 09, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, July 09, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”) (NYSE American: CLDI), a clinical-stage biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding Series A, Series B-1, Series C-1, Series D, Series E and Series F Warrants (the “Existing Warrants”) to purchase up to an aggregate of 6,595,000 shares of the Company's common stock at a reduced exercise price of $0.70. The gross proceeds to the Company from …
Read More
Calidi Biotherapeutics, Inc. (CLDI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
Published: May 16, 2025 by: Zacks Investment Research
Sentiment: Neutral
Calidi Biotherapeutics, Inc. (CLDI) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Read More
Calidi Biotherapeutics Announces Pricing of $3.9 Million Registered Direct Offering and Concurrent Private Placement
Published: March 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (NYSE AMERICAN: CLDI) (“Calidi” or the “Company”), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced that it has entered into a definitive securities purchase agreement with a single institutional investor for the purchase and sale of 3,325,000 shares of the Company's common stock at a per share purchase price of $0.65, and at the election of the investor, in lieu of the common stock, pre-funded warrants to purchase up to 2,728,000 shares of Common Stock at a price of $0.649 per pre-funded warrant, which …
Read More
Calidi Biotherapeutics and OS Therapies Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published: February 28, 2025 by: Accesswire
Sentiment: Neutral
ORLANDO, FLORIDA / ACCESS Newswire / February 28, 2025 / RedChip Companies will air interviews with Calidi Biotherapeutics, Inc. (NYSE American:CLDI) and OS Therapies Inc. (NYSE American:OSTX) on the RedChip Small Stocks, Big Money™ show, a sponsored program on Bloomberg TV this Saturday, March 1, at 7 p.m. Eastern Time (ET).
Read More
Calidi Biotherapeutics Announces Commencement of Recruitment for Multiple Dose CLD-101 Trial in Patients with Newly Diagnosed High Grade Glioma at Northwestern University Hospital
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
SAN DIEGO, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, today announced that Northwestern University/Northwestern Memorial Hospital is starting recruitment for the CLD-101 clinical trial of its immunotherapy product.
Read More
About Calidi Biotherapeutics, Inc. (CLDI)
- IPO Date 2021-11-01
- Website https://calidibio.com
- Industry Biotechnology
- CEO Eric E. Poma
- Employees 28